Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25015641 | 0.77 | ABCB1 (0.47) | TSHRALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL8870482 | 0.70 | HSD17B10 (0.62) | TSHRALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL8603065 | 0.68 | KDM4E (0.48) | TSHRALDH1A1HPGDMAPTSHMT2 | |
| SCHEMBL15272024 | 0.67 | ALDH1A1 (0.47) | TSHRALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL23784821 | 0.67 | ALDH1A1 (0.46) | TSHRALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL7466112 | 0.66 | ALDH1A1 (0.48) | TSHRALDH1A1HPGDMAPTKDM4E | |
| SCHEMBL10291568 | 0.65 | GRIA1 (0.41) | TSHRALDH1A1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL2276946 | 0.65 | KMT2A (0.45) | TSHRALDH1A1HPGDMAPTSHMT2 | |
| SCHEMBL9851153 | 0.65 | ALDH1A1 (0.52) | TSHRALDH1A1HPGDMAPTSHMT2 | |
| SCHEMBL7243986 | 0.64 | L3MBTL1 (0.50) | TSHRALDH1A1HPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-12-11 | — | — | US | disclosed |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-09-20 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| EP-3110824-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127548-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | TSHR 3022/4885ALDH1A1 2688/4885HPGD 2983/4885 |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TSHR 3022/4885ALDH1A1 2688/4885HPGD 2983/4885 |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TSHR 3022/4885ALDH1A1 2688/4885HPGD 2983/4885 |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TSHR 3022/4885ALDH1A1 2688/4885HPGD 2983/4885 |
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | TSHR 3022/4885ALDH1A1 2688/4885HPGD 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.